The past year has been
extremely eventful
Promising findings from VAL001 phase I/IIa clinical trial
Two-year survival is significantly higher for patients treated with VAL001, compared with the reference population.
Two-year survival is significantly higher for patients treated with VAL001, compared with the reference population.
Respiratorius AB (publ) develops drug candidates with the goal of launching or out-licensing drugs for the treatment of cancer, chronic obstructive pulmonary disease (COPD) and severe asthma.
In the field of oncology, Respiratorius is developing a new drug as a pretreatment to enhance the effects of the standard treatment currently used for the treatment of diffuse large B-cell lymphoma, the most common type of aggressive lymphoma.
In the field of COPD and asthma, Respiratorius has developed compound series with a demonstrated bronchodilating effect on human lung tissue. The Company’s project portfolio also contains a substance developed for use in PET imaging, aimed at facilitating the diagnosis of certain cardiovascular diseases.
Respiratorius was founded in 1999 as a research spin-out from Lund University. Since 2012, Respiratorius is a public company listed on the Spotlight Stock Market (formerly Aktietorget).
Respiratorius develops effective new drugs to treat the common diseases cancer, COPD and severe asthma, as well as improved cardiovascular diagnostics. The Company bases its operations on patent-pending substances that have shown superior results in preclinical studies compared with the “gold standard.”
Respiratorius’ vision is to help reduce the global burden of disease for the three major diseases cancer, respiratory diseases and cardiovascular diseases.
The Company’s goal and driving force is to develop innovative new drugs to improve quality of life and survival time for patients suffering from cancer, chronic obstructive pulmonary disease (COPD) and severe asthma, as well as improved cardiovascular diagnostics. By doing so, the Company will also create long-term shareholder value.
Respiratorius will be an attractive partner for academic research groups, biotech companies and global pharmaceutical companies through our unique expertise, with a focus on the early part of the value chain – from academic research to finished product on the market.
Respiratorius searches at an early phase for strategic partners who assume financial and operational responsibility from development to finished product. This type of partner will have financial resources, experience in large clinical studies and established contacts with regulatory authorities. These partners will also be responsible in the future for manufacturing, marketing and sales of the licensed drugs that may result from the development project. Several large pharmaceutical companies have already shown interest regarding licensing and collaboration on the Company’s projects.
A license agreement with a pharmaceutical company is expected to give Respiratorius income in the form of an initial payment followed by milestone payments, as well as royalties. In the event that an agreement is concluded, there is an intention among the major shareholders to distribute approximately half of the advance payment in connection with a license agreement pro rata to all shareholders, provided that the Company’s operations remain intact.
The timing of signing cooperation agreements with pharmaceutical companies will entail business decisions based on cost, risk, skill requirements and the value that would be added by completing additional steps in-house. Such cooperation agreements will ensure that the projects receive expertise and resources from pharmaceutical companies at an early stage. With this approach, Respiratorius avoids tying up excessive resources in a single project. It is in the best interest of the Company to work – without compromising on safety, expertise or quality – to minimize time to market for its drugs.
The Company operates based on a virtual model, without any employees. Resource and skill requirements vary during project development and are purchased as needed. This organizational model is totally focused on value-generating project development.
Respiratorius AB (publ) develops drug candidates with the goal of launching drugs to treat common diseases such as cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The project portfolio also includes a project for improving the diagnosis of certain cardiovascular diseases using PET imaging.
Respiratorius AB
Medicon Village
Scheelevägen 2, 223 81 Lund, Sweden
info@respiratorius.com
+46 70 922 41 40